Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion reported that all patients in the EVX-01 phase 2 advanced melanoma trial maintained their clinical responses at three-year follow-up, with no tumor progression observed. The data build on two-year results showing a 75% objective response rate, a 25% complete response rate, and tumor reduction in 15 of 16 enrolled patients; third-year patients received EVX-01 as stand-alone therapy.
Key figures
- Drug Name
- EVX-01
- Phase Of Trial
- Phase 2
- Extension responders
- 6 of 12 responders
- Complete response rate
- 25%
- Objective response rate
- 75%
- Tumor reduction patients
- 15 of 16
- Neoantigens with tcell response
- 86%
- Patients with deepened response
- 54%
- Patients responding at two years
- 92%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.